All In MedTech

Device Trial Radar · NCT02107326

Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes

Webdia Study: Use of Smartphones to Improve Diabetes Control and Quality of Life in Children With Type 1 Diabetes

Last checked: Nov 19, 2026Latest source record: Oct 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

May 2014

Primary completion

Aug 15, 2017

Study completion Oct 1, 2017

Sponsor

Lead sponsor
Philippe KleeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 8, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 10 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the impact of a software for smartphones and tablets on type 1 diabetes control and quality of life

Conditions

  • Type 1 Diabetes
  • Quality of Life
  • Hypoglycaemia

Interventions

  • Webdia SoftwareDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of Webdia Software use on HbA1CTime frame: 0, 3, 6 and 9 months after inclusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital of Geneva

    Geneva, Canton of Geneva, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.